– Bloomberg
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $72 Price Target
Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $72 price target.
Related Posts
Illumina Slapped With €400M In Fines: European Commission Penalizes Company For Hasty Grail Deal
The European Commission has fined Illumina Inc (NASDAQ: ILMN) and Grail Inc approximately €432 million and €1,000, respectively, for implementing their proposed merger before approval by the commission, in breach of EU
Elon Musk Digs The Idea Of A Monster Cybertruck: ‘Not Bad…’
Tesla Inc (NASDAQ:TSLA) CEO Elon Musk on Monday responded to a Cybertruck stainless steel body mounted on monster…
Bitcoin Trades Above This Key Level; Shiba Inu Emerges As Top Gainer
Bitcoin (CRYPTO: BTC) traded slightly higher this morning, with the cryptocurrency prices trading above the $21,300 level on Wednesday.